JP2017533207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533207A5 JP2017533207A5 JP2017522170A JP2017522170A JP2017533207A5 JP 2017533207 A5 JP2017533207 A5 JP 2017533207A5 JP 2017522170 A JP2017522170 A JP 2017522170A JP 2017522170 A JP2017522170 A JP 2017522170A JP 2017533207 A5 JP2017533207 A5 JP 2017533207A5
- Authority
- JP
- Japan
- Prior art keywords
- slamf1
- antibody
- activated
- cells
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067638P | 2014-10-23 | 2014-10-23 | |
| US62/067,638 | 2014-10-23 | ||
| US201562155810P | 2015-05-01 | 2015-05-01 | |
| US62/155,810 | 2015-05-01 | ||
| PCT/US2015/056714 WO2016065038A1 (en) | 2014-10-23 | 2015-10-21 | Slamf1 antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533207A JP2017533207A (ja) | 2017-11-09 |
| JP2017533207A5 true JP2017533207A5 (https=) | 2018-11-29 |
Family
ID=54397011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522170A Pending JP2017533207A (ja) | 2014-10-23 | 2015-10-21 | Ｓｌａｍｆ１アンタゴニスト及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180016555A1 (https=) |
| EP (1) | EP3209688A1 (https=) |
| JP (1) | JP2017533207A (https=) |
| CN (1) | CN108064166A (https=) |
| WO (1) | WO2016065038A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| NZ739090A (en) | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| TWI690538B (zh) * | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| WO2019184909A1 (zh) * | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN114008077B (zh) * | 2019-07-03 | 2024-10-29 | 牛津生物疗法有限公司 | 抗体和使用方法 |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| CN113899903B (zh) * | 2020-07-06 | 2025-08-29 | 上海市免疫学研究所 | 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用 |
| CN116284405B (zh) * | 2023-03-15 | 2024-03-19 | 中国科学技术大学 | 靶向cd150蛋白的纳米抗体及其应用 |
| CN116162653A (zh) * | 2023-03-30 | 2023-05-26 | 湖北省农业科学院畜牧兽医研究所 | 靶向切除猪SlamF1基因编码区DNA的成对编辑位点、使用方法及其应用 |
| KR20250177034A (ko) * | 2024-06-13 | 2025-12-23 | 성균관대학교산학협력단 | 인간 slamf1 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0795014B1 (en) * | 1994-12-02 | 2008-01-16 | Schering Corporation | Costimulatory T cell surface antigen SLAM |
| US5576423A (en) * | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| WO2004024097A2 (en) * | 2002-09-16 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2012121429A1 (ko) * | 2011-03-07 | 2012-09-13 | 연세대학교 산학협력단 | 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 nmd-무관 암 세포 바이오 마커 |
-
2015
- 2015-10-21 EP EP15790387.3A patent/EP3209688A1/en not_active Withdrawn
- 2015-10-21 CN CN201580070049.7A patent/CN108064166A/zh active Pending
- 2015-10-21 JP JP2017522170A patent/JP2017533207A/ja active Pending
- 2015-10-21 WO PCT/US2015/056714 patent/WO2016065038A1/en not_active Ceased
- 2015-10-21 US US15/520,998 patent/US20180016555A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533207A5 (https=) | ||
| JP2018512430A5 (https=) | ||
| Buchan et al. | The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy | |
| Mahoney et al. | Combination cancer immunotherapy and new immunomodulatory targets | |
| Lee et al. | Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses | |
| Lu | OX40 and OX40L interaction in cancer | |
| JP2019528082A5 (https=) | ||
| Pasero et al. | Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity | |
| JP2017511379A5 (https=) | ||
| CN113260368A (zh) | 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途 | |
| JP7240808B2 (ja) | Ｐｓｇｌ－１モジュレーターおよびその使用 | |
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| US11939367B2 (en) | BTLA fusion protein agonists and uses thereof | |
| Chowdhury et al. | Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial | |
| Ababneh et al. | Tumor necrosis factor superfamily signaling: life and death in cancer | |
| Patel et al. | Prominent targets for cancer care: immunotherapy perspective | |
| TW201840590A (zh) | 嵌合多肽及改變其膜定位之方法 | |
| Shuptrine et al. | Shining a LIGHT on myeloid cell targeted immunotherapy | |
| Ye et al. | Immune checkpoint blockade for cancer therapy: current progress and perspectives | |
| Schreiner et al. | Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo | |
| Huang et al. | The breakthroughs in cancer immune checkpoint based therapy: a review of development in immune checkpoint study and its application | |
| HRP20210383T1 (hr) | Kombinirana terapija za rak | |
| Duhen et al. | AGONISTIC ANTIBODIES IN CANCER IMMUNOTHERAPY | |
| Kornbluth et al. | Multimeric Soluble 4-1BBL as a T Cell Stimulator for Adoptive Immunotherapy | |
| Foks | Regulation of immune responses in atherosclerosis |